| Christopher James Bruce, MD | |
|
708 N Shady Retreat Rd Ste 8, Doylestown, PA 18901 | |
| (215) 863-8287 | |
| Not Available |
| Full Name | Christopher James Bruce |
|---|---|
| Gender | Male |
| Speciality | Colorectal Surgery (proctology) |
| Experience | 35 Years |
| Location | 708 N Shady Retreat Rd Ste 8, Doylestown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487743027 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD432700 (Pennsylvania) | Secondary |
| 208C00000X | Colon & Rectal Surgery | MD432700 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doylestown Hospital Visiting Nurse/hcd | Doylestown, PA | Home health agency |
| Doylestown Hospital | Doylestown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Via Affiliates | 1759295512 | 182 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making sure insurance protects people who have preexisting health conditions.
› Verified 7 days ago
| Entity Name | Via Affiliates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003446261 PECOS PAC ID: 1759295512 Enrollment ID: O20031117000104 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making sure insurance protects people who have preexisting health conditions.
› Verified 7 days ago
| Entity Name | Suburban Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710355029 PECOS PAC ID: 6204145642 Enrollment ID: O20151026000795 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making sure insurance protects people who have preexisting health conditions.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher James Bruce, MD P O Box 829641, Philadelphia, PA 19182-0001 Ph: (267) 370-5296 | Christopher James Bruce, MD 708 N Shady Retreat Rd Ste 8, Doylestown, PA 18901 Ph: (215) 863-8287 |
News Archive
New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making sure insurance protects people who have preexisting health conditions.
› Verified 7 days ago